Trial Profile
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Ripretinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms Intrigue
- Sponsors Deciphera Pharmaceuticals
- 01 Feb 2024 Results of exploratory analysis of ctDNA biomarker , published in the Nature Medicine
- 20 Jan 2024 Results (Data cutoff was March 15, 2023) assessing safety and efficacy of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib presented at the 2024 Gastrointestinal Cancers Symposium
- 18 Jan 2024 According to a Deciphera Pharmaceuticals media release, the company will presented new long-term final results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium